These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 17435425

  • 21. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Arias L, Ruiz-Moreno JM, Gómez-Ulla F, Fernández M, Montero J.
    Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
    [Abstract] [Full Text] [Related]

  • 22. The cost of vision for vitreoretinal interventions.
    Smiddy WE.
    Curr Opin Ophthalmol; 2008 May; 19(3):195-201. PubMed ID: 18408493
    [Abstract] [Full Text] [Related]

  • 23. The burden of age-related macular degeneration: a value-based medicine analysis.
    Brown GC, Brown MM, Sharma S, Stein JD, Roth Z, Campanella J, Beauchamp GR.
    Trans Am Ophthalmol Soc; 2005 May; 103():173-84; discussion 184-6. PubMed ID: 17057801
    [Abstract] [Full Text] [Related]

  • 24. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1.
    Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N.
    Am J Ophthalmol; 2008 Feb; 145(2):239-248. PubMed ID: 18222192
    [Abstract] [Full Text] [Related]

  • 25. Ranibizumab for treatment of choroidal neovascularization secondary to age-related macular degeneration.
    Bhatnagar P, Spaide RF, Takahashi BS, Peragallo JH, Freund KB, Klancnik JM, Cooney MJ, Slakter JS, Sorenson JA, Yannuzzi LA.
    Retina; 2007 Sep; 27(7):846-50. PubMed ID: 17891007
    [Abstract] [Full Text] [Related]

  • 26. Subfoveal exudative age-related macular degeneration: evidence for preoccult disease.
    Shah AR, Del Priore LV.
    Curr Opin Ophthalmol; 2009 May; 20(3):182-7. PubMed ID: 19367162
    [Abstract] [Full Text] [Related]

  • 27. Is significant relevant? Validity and patient benefit of randomized controlled clinical trials on age-related macular degeneration.
    Joussen AM, Lehmacher W, Hilgers RD, Kirchhof B.
    Surv Ophthalmol; 2007 May; 52(3):266-78. PubMed ID: 17472802
    [Abstract] [Full Text] [Related]

  • 28. Value-based medicine.
    Kymes SM, Vollman D, Frick KD.
    Ophthalmology; 2008 Nov; 115(11):2099; author reply 2100. PubMed ID: 19068385
    [No Abstract] [Full Text] [Related]

  • 29. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U.
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [Abstract] [Full Text] [Related]

  • 30. The cost-effectiveness of treatment of age-related macular degeneration: a review.
    Kymes Steven M.
    Minerva Med; 2009 Feb; 100(1):69-78. PubMed ID: 19277005
    [Abstract] [Full Text] [Related]

  • 31. Reproducibility of gradings of retinal photographs in eyes with subfoveal choroidal neovascularization and age-related macular degeneration in the macular photocoagulation study.
    Jefferys JL, Alexander J, Hiner CJ, Javornik NB, Smith RE, Bressler NM, Hawkins BS.
    Ophthalmic Epidemiol; 2008 Feb; 15(3):191-201. PubMed ID: 18569815
    [Abstract] [Full Text] [Related]

  • 32. Macular microcirculation blood flow in patients with age related macular degeneration treated with photodynamic therapy and transpupillary thermotherapy.
    Kubicka-Trzaska A.
    Klin Oczna; 2007 Feb; 109(4-6):138-41. PubMed ID: 17725271
    [Abstract] [Full Text] [Related]

  • 33. Quality of life and health economic assessments of age-related macular degeneration.
    Covert D, Berdeaux G, Mitchell J, Bradley C, Barnes R.
    Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S20-5. PubMed ID: 17240252
    [Abstract] [Full Text] [Related]

  • 34. Update on utilities and cost-utility analyses.
    Hollands H, Sharma S.
    Curr Opin Ophthalmol; 2006 Jun; 17(3):223-7. PubMed ID: 16794433
    [Abstract] [Full Text] [Related]

  • 35. Characteristics of choroidal neovascularization in the complications of age-related macular degeneration prevention trial.
    Maguire MG, Alexander J, Fine SL, Complications of Age-related Macular Degeneration Prevention Trial (CAPT) Research Group.
    Ophthalmology; 2008 Sep; 115(9):1468-73, 1473.e1-2. PubMed ID: 18486222
    [Abstract] [Full Text] [Related]

  • 36. [Ranibizumab for treatment of exudative age-related macular degeneration--own experience].
    Wykrota H, Gierek-Lapińska A, Trzciakowski K, Gajdzik-Gajdecka U.
    Klin Oczna; 2007 Sep; 109(10-12):402-9. PubMed ID: 18488382
    [Abstract] [Full Text] [Related]

  • 37. Ranibizumab: new drug. Macular degeneration: second-line use due to risks.
    Prescrire Int; 2008 Feb; 17(93):3-6. PubMed ID: 18354841
    [Abstract] [Full Text] [Related]

  • 38. 56,000 Ways? No way!
    Brown GC.
    Curr Opin Ophthalmol; 2006 Jun; 17(3):219-22. PubMed ID: 16794432
    [No Abstract] [Full Text] [Related]

  • 39. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
    Ciulla TA, Rosenfeld PJ.
    Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
    [Abstract] [Full Text] [Related]

  • 40. Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999.
    Coleman AL, Yu F.
    Ophthalmology; 2008 Jan; 115(1):18-25. PubMed ID: 17572499
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.